Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2a Study Evaluating the Safety, Pharmacokinetics, and Efficacy of ABT-263 in Subjects With Small Cell Lung Cancer or Other Non-Hematological Malignancies

NCT00445198 is registered in ClinicalTrials.gov with AbbVie (prior sponsor, Abbott) as lead sponsor.

NCT NCT00445198
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00445198 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2a Study Evaluating the Safety, Pharmacokinetics, and Efficacy of ABT-263 in Subjects With Small Cell Lung Cancer or Other Non-Hematological Malignancies
Lead sponsor
AbbVie (prior sponsor, Abbott)
Phase
Phase 1/2
Overall status
Completed
Start date
April 30, 2007
Completion date
December 31, 2010
Enrollment
86 (actual)
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

small cell lung cancer, small cell lung carcinoma